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Abstract
Background: Medication review is often recommended to optimize medication use. In clinical practice it is mostly
operationalized as an intervention without co-interventions during a short term intervention period. However, most
systematic reviews also included co-interventions and prolonged medication optimization interventions.
Furthermore, most systematic reviews focused on specific patient groups (e.g. polypharmacy, elderly, hospitalized)
and/or on specific outcome measures (e.g. hospital admissions and mortality). Therefore, the objective of this study
is to assess the effectiveness of medication review as an isolated short-term intervention, irrespective of the patient
population and the outcome measures used.
Methods: A literature search was performed in MEDLINE, EMBASE and Web of Science from their inception
through September 2015. Randomized controlled trials (RCTs) with medication review as isolated short term
intervention (<3 months) were included. There were no restrictions with regard to patient characteristics and
outcome measures. One reviewer extracted and a second checked data. The risk of bias of studies was evaluated
independently by two reviewers. A best evidence synthesis was conducted for every outcome measure used in
more than one trial. In case of binary variables a meta-analysis was performed in addition to the best evidence
synthesis, to quantify the effect.
Results: Thirty-one RCTs were included in this systematic review (55% low risk of bias). A best evidence synthesis
was conducted for 22 outcome measures. No effect of medication review was found on clinical outcomes
(mortality, hospital admissions/healthcare use, the number of patients falling, physical and cognitive functioning),
except a decrease in the number of falls per patient. However, in a sensitivity analysis using a more stringent
threshold for risk of bias, the conclusion for the effect on the number of falls changed to inconclusive. Furthermore
no effect was found on quality of life and evidence was inconclusive about the effect on economical outcome
measures. However, an effect was found on most drug-related problems: medication review resulted in a decrease
in the number of drug-related problems, more changes in medication, more drugs with dosage decrease and a
greater decrease or smaller increase of the number of drugs.
Conclusions: An isolated medication review during a short term intervention period has an effect on most
drug-related outcomes, minimal effect on clinical outcomes and no effect on quality of life. No conclusion can be
drawn about the effect on economical outcome measures. Therefore, it should be considered to stop performing
cross-sectional medication reviews as standard care.
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Background
In order to reduce the number of preventable adverse
drug events and hospital admissions, medication re-
view is often recommended, incorporated in several
guidelines and also frequently reimbursed by health
care insurers in various countries [1–10]. Medication
review is defined by the Pharmaceutical Care Network
Europe (PCNE) as “a structured evaluation of a pa-
tient‘s medicines with the aim of optimising medi-
cines use and improving health outcomes. This entails
detecting drug related problems and recommending
interventions” [11]. In clinical practice, for each indi-
vidual patient, medication review is mostly operation-
alized as an isolated intervention during a short term
intervention period [5, 6, 9, 12, 13].
Several systematic reviews and meta-analyses already
examined the effectiveness of medication review and
these did not unequivocally prove the effectiveness of
medication review [14–23]. However, these systematic
reviews did not only include trials assessing the effect
of medication review in terms of how it is mostly
operationalized in practice: an isolated cross-sectional
assessment of total medication use during a short
term intervention period less than 3 months. Most
trials in the systematic reviews assessed the effect of
medication review as part of multi-faceted pharma-
ceutical care interventions, consisting of for instance
transitional care, adherence counseling and education
of patients and healthcare professionals, besides medi-
cation review. Such interventions also often last lon-
ger than 3 months. Furthermore, most systematic
reviews focus on specific patient groups (e.g. poly-
pharmacy, elderly, hospitalized) and/or on specific
outcome measures (e.g. hospital admissions and mor-
tality). As a result, more insight is necessary in the
effectiveness of medication review as an isolated
short-term intervention on clinical outcomes, quality
of life, drug-related and economical outcomes.
Therefore, this systematic review aims to summarize
the evidence of medication reviews as performed in
clinical practice, irrespective of patient characteristics,
setting and outcome measures.
Methods
This systematic review, assessing the effectiveness of
medication review, irrespective of the outcome measures
used, follows the PRISMA-guidelines [24, 25].
Data sources and searches
A literature search was performed in MEDLINE,
EMBASE and Web of Science from their inception
through September 2015. For the development of the
search strategy and the full electronic search, see
Additional file 1.
Study selection
The inclusion criteria were operationalized based on the
PICO model. No restrictions were set concerning the P
(patients) and O (outcome measures): interventions
could be conducted in any setting and there were no
restrictions with regard to patient characteristics and
outcome measures. The I (intervention) had to be medi-
cation review, which was defined as follows: a structured
cross-sectional assessment of a patient’s total medication
use leading to recommendations that had to be dis-
cussed with the patient and/or clinician within 3 months,
in order to improve safety, efficacy or cost-effectiveness.
Medication review had to be the single intervention; co-
interventions with potential impact on the outcome
measures (e.g. discharge counseling, transitional care,
non-pharmacological interventions) were not allowed.
The C (comparison) was defined as usual care. In
addition to PICO the following study selection criteria
were formulated: trials had to be randomized controlled
trials (RCTs) and only full-length articles were consid-
ered for inclusion in this review. Two reviewers inde-
pendently selected titles/abstracts and the corresponding
full text articles to be included in this systematic review.
Discrepancies in judgment were discussed in order to
reach consensus (VH-BvdB) about final inclusion.
Data extraction and risk of bias assessment
Relevant data on study characteristics and outcomes
were extracted by one reviewer (VH) and checked by a
second reviewer (NW). P-values ≤0.05 were considered
as statistically significant.
Two reviewers independently assessed the risk of bias
of the studies eligible for inclusion by using the checklist
with criteria for risk of bias from the Cochrane Back
Review Group [26, 27]. To determine whether a study
had a low risk of bias (LRB) or a high risk of bias (HRB),
a consensus (VH-BvdB) based scorings method was
developed based on the risk of bias assessment.
The twelve Cochrane criteria [26, 27] were designated
essential (4) or non-essential (8) in relation to research
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on medication review by a consensus discussion (VH-
BvdB). Essential criteria were: was the method of
randomization adequate?; Was the drop-out rate de-
scribed and acceptable?; Were the groups similar at
baseline regarding the most important prognostic indica-
tors?; Were co-interventions avoided or similar?. To be
considered a study with a low risk of bias, all the essen-
tial Cochrane criteria had to be scored positive, whereas
a total of at least 6 of the 12 criteria (50%) had to be
scored positive. A cutoff of 50% was chosen, as it is not
feasible for medication review trials to score positive on
certain criteria, like: “was the patient blinded to the
intervention”; “was the care provider blinded to the
intervention”; “was the outcome assessor blinded to the
intervention”. Discrepancies in judgment were discussed
in order to reach consensus (VH-BvdB) about the desig-
nation of low or high risk of bias for each criterion for
each study. If for a specific study an “unclear risk of
bias” was scored for the same criterion by both re-
viewers, the criterion was designated “high risk of bias.
The inter-rater agreement of the assessment of risk of
bias was assessed by calculating the Cohen’s kappa.
A sensitivity analysis was performed regarding a more
stringent cut-off point for risk of bias. The actually used
cut-off point for risk of bias was compared with a
threshold of ≥8 (2/3 of the attainable 12) of the criteria
to be scored positive for a study to be considered a study
with a low risk of bias.
Data synthesis and analysis
An adapted version from previously published best
evidence syntheses [28, 29] was conducted for every
outcome measure used in more than one trial, com-
bining a) the percentage of intervention patients in-
cluded in studies showing effect on the outcome
measure and b) the risk of bias of the set of trials
using the outcome measure.
The following methodology was used for this purpose:
1) First, for each outcome measure, the percentage of
intervention patients included in studies showing
effect on the outcome measure was calculated
2) The risk of bias of a set of studies per outcome
measure was subsequently determined as follows: if
50% or more of the intervention patients included in
trials using the outcome measure had a low risk of
bias, the set of studies was designated overall low
risk of bias
3) Finally, both the percentage of intervention patients
included in studies showing effect on the outcome
measure and the risk of bias score for the set of trials
per outcome measure were combined to conclude
whether medication review has effect on the outcome
measure by using the method depicted in Fig. 1.
In case of binary variables a meta-analysis was per-
formed in addition to the best evidence synthesis, to
quantify the effect. In these meta-analyses, effect sizes of
binary variables were pooled using their weighted aver-
age for the treatment effect (using a random-effect
meta-analysis method). Forest plots were created with
STATA version 13.1 to summarize the risk ratio (RR)
and the 95% confidence interval (CI). Heterogeneity
across studies was assessed using I2 statistics (studies
with an I2 > 50% were considered heterogeneous). Out-
come measures reported in only one trial were reported
descriptively.
A sensitivity analysis was performed with regard to the
impact of large trials with a high risk of bias, on every
individual outcome measure. In this sensitivity analysis,
large trials with a high risk of bias, with a number of
intervention patients greater than the median number of
intervention patients per outcome measure, were ex-
cluded from the best evidence synthesis.
Fig. 1 Schematic representation of the best evidence synthesis. Schematic representation of the best evidence synthesis, combining a) the
percentage of intervention patients included in studies showing effect on the outcome measure and b) the risk of bias of the set of trials using
the outcome measure. For details: see Additional file 4
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Results
The literature search provided a total of 13,870 poten-
tially relevant publications which were screened for eligi-
bility. After screening titles and abstracts, 154 articles
were left for full text screening. After this screening, 31
RCTs met the inclusion criteria and were included in
this systematic review. A flow diagram of the literature
search is represented in Fig. 2.
An overview of the study characteristics of the included
studies is depicted in Table 1. Most studies were con-
ducted in primary care (52%), sample size ranged from 64
to 2014 patients, the observation period ranged from 0 to
12 months and 17 (58%) of the trials were conducted in
Europe and 7 (23%) in the United States. Patients were
involved in the medication reviews in 21 of the 31 studies,
the mean age (as reported in 24/31 trials) and the number
of drugs (as reported in 18/31 studies) of the intervention
patients in each trial ranged from 51.4 to 87.0 years and
from 4 to 14 drugs, respectively.
Seventeen studies (55%) met the criteria for low risk of
bias. The inter-rater agreement between the two assessors
of risk of bias was 0.74 (Cohen’s Kappa). Most common
reasons for designating studies high risk of bias were
methodological shortcomings on “compliance”, “treatment
allocation concealment”, “blindness of patient, care pro-
vider and outcome assessor”, “randomization”, “similarity
of study groups at baseline” and “drop-out rate”.
Clinical outcomes
As summarized in Fig. 3, no effect of medication review
was found on clinical outcomes, except for a decrease in
the number of falls.
Mortality
Eleven trials (overall low risk of bias, including 2403 inter-
vention patients) assessed the effect of medication review
on mortality (for details, see Additional file 2: Table S1).
Data were pooled in a meta-analysis (Additional file 2:
Figure S1) and with a RR of 0.94 (CI, 0.76–1.17) no
effect of medication review on mortality was found.
Moderate heterogeneity was found between the trials
(I2 = 22.0%, P = 0.234).
Fig. 2 Flow diagram of the literature search and study selection process
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Hospital admissions and healthcare use
Data of 11 trials (Additional file 2: Table S2), including
2041 intervention patients, showed evidence with a low
risk of bias for no effect of medication review on the
number of hospital admissions (including emergency
admissions and visits). Meta-analysis of data from five
trials with overall low risk of bias, including 2000 in-
tervention patients, assessing the effect of medication
review on the number of patients admitted to the hos-
pital revealed no effect, with a RR of 0.94 (0.82, 1.08)
and with moderate heterogeneity (I2 = 42.3%, P = 0.139)
(Additional file 2: Figure S2 and Table S3). The same
applies to the time to first (re)admission in three trials
with low risk of bias, including 518 intervention
patients, except for a subgroup with only emergency
department visits or a low baseline risk for hospital
admission (Additional file 2: Table S4) [30, 31]. In
addition, no effect of medication review was found on
the length of hospital stay in seven trials with overall
high risk of bias, including 1330 intervention patients
and the number of emergency admissions/visits in seven
trials with overall low risk of bias, including 1243
intervention patients (Additional file 2: Tables S5 to S6).
Furthermore, no effect of medication review was demon-
strated on the number of General Practitioner (GP) visits
in 6 trials with low risk of bias including 1582 interven-
tion patients and on the number of outpatient visits in
four trials with overall low risk of bias, including 1144
intervention patients (Additional file 2: Tables S7 to S8).
The meta-analysis of data of 2 trials with overall high
risk of bias, including 825 intervention patients, found
no effect on the number of patients admitted to residen-
tial homes with a RR of 1.17 (0.79, 1.74), with limited
heterogeneity (I2 = 0.0%, p = 0.997) (Additional file 2:
Figure S3 and Table S9).
No best evidence synthesis could be conducted for
a variety of other healthcare use related outcome
measures used in only one trial. In six trials no effect
was found on these outcome measures [30, 32–37],
whereas in two trials an effect was found only in a
subdomain of healthcare use related outcome mea-
sures or a subgroup of patients [32, 38] and in one
trial a positive effect was found in favor of patients
receiving usual care [30].
Falls
It was observed in two trials with overall low risk of bias,
including 467 intervention patients, that medication
review decreases the number of falls per patient
(Additional file 2: Table S10). Data of four trials with
overall low risk of bias, including 929 intervention pa-
tients, were pooled in a meta-analysis (Additional file 2:
Figure S4). This meta-analysis suggested that medication
review decreases the number of patients falling (RR 0.68
(0.52, 0.90); I2 = 41.0%, p = 0.166). However, the best
evidence synthesis was inconclusive about the effect on
the number of patients falling (Additional file 2: Table
S11). Furthermore, a significant lower fall rate per 1000
patient days (only assessed by Michalek et al) due to
medication review was found [39].
Fig. 3 Effect of medication review on clinical outcome measures as assessed in more than 1 trial. The percentage of intervention patients is
shown on the y-axis. The black part of the bar represents the percentage of intervention patients included in a trial with a positive effect on a
specific outcome measure. The outcome measures, the number of trials using the specific outcome measure, the overall risk of bias of the set of
evidence per outcome measure and the conclusion of the best evidence synthesis are shown on the x –axis. T = trials; LRB = low risk of bias; HRB
= High risk of bias; inconcl. = inconclusive
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Health status, physical and cognitive outcome measures
Three trials with low risk of bias, including 499 inter-
vention patients, showed no effect of medication re-
view on physical functioning using the Barthel index
(Additional file 2: Table S12). This was confirmed in
one study, using three different outcome measures for
physical functioning [40].
Medication review neither improved clinical status [41],
health status [40] and patient’s perception of severity of
illness [41]. In one study, however, a smaller decrease in
self-rated health due to medication review was found [35].
Two trials, with overall low risk of bias, including 449
intervention patients, found no effect of medication
review on cognitive functioning, using the Standard
Mini Mental State Examination (Additional file 2: Table
S13). Medication review also did not affect cognitive
functioning, expressed with other outcome measures
[40, 42, 43], except for the Chrichton-Royal Behaviour
Rating Scale [42].
Quality of life
The effect of medication review on quality of life is
outlined in Fig. 4. There is evidence with overall low risk
of bias that medication review has no effect on quality
of life, as measured with the EQ-5D score (based on six
trials, including 1583 intervention patients) or the SF-36
score (based on two trials, including 547 intervention
patients), whereas evidence with overall high risk of bias
was inconclusive about the effect of medication review
on the EQ5D-VAS (used in five trials, including 798
intervention patients) (Additional file 2: Table S14). Pit
et al also found no effect of medication review on quality
of life measured with the SF-12 score [44].
Drug-related outcome measures
The effect of medication review on drug-related out-
come measures is represented in Fig. 4. An effect of
medication review was found on most drug-related out-
come measures (the number of drugs, the number of
drug changes, the number of drug-related problems and
the number of drugs with a dosage decrease), but not on
the number of drugs with dosage increase.
Drug-related problems
In four trials with overall high risk of bias, including 599
intervention patients, medication review decreases the
number of drug-related problems (Additional file 2:
Table S15). The results of two trials assessing the effect
of medication review on the number of patients with
drug-related problems (with different pre-defined drug-
related problems per trial) were conflicting [45, 46].
Number of drug changes and number of drugs with a
dosage decrease or increase
Data of three trials with low risk of bias, including 965
intervention patients, showed an increase of the number
Fig. 4 Effect of medication review on quality of life, drug-related outcome measures and economical outcome measures as assessed in more
than one trial. The percentage of intervention patients is shown on the y-axis. The black part of the bar represents the percentage of intervention
patients included in a trial with a positive effect on a specific outcome measure. The outcome measures, the number of trials using the specific
outcome measure, the overall risk of bias of the set of evidence per outcome measure and the conclusion of the best evidence synthesis are
shown on the x-axis. T = trials; LRB = low risk of bias; HRB = High risk of bias; inconcl. = inconclusive
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of drug changes as a result of medication review
(Additional file 2: Table S16). Two other trials with
overall high risk of bias, including 486 intervention
patients, found an increase of the number of drugs with a
dosage decrease, whereas no difference was found with
regard to the number of drugs with dosage increase
(Additional file 2: Tables S17 to S18).
Number of drugs and doses
Twelve studies with overall low risk of bias, including
1972 intervention patients, found that medication review
leads to a greater decrease or smaller increase of the
number of drugs used (Additional file 2: Table S19). Sell-
ors et al, however, found no difference in the absolute
number of drugs used after 5 months due to medication
review [37]. Furthermore, no effect of medication review
was found on the number of individual doses per day
[47] and the dosing frequency per day [48].
Other drug-related outcome measures
Various outcome measures, only used in one trial, but
covering the same outcome domains, could not be in-
corporated in a best evidence synthesis. Two studies
assessing the effect of medication review on adherence
and knowledge found conflicting results [41, 47]. Results
with regard to appropriate prescribing and medication
use were also conflicting. In two trials, medication
review did not improve a set of predefined indicators of
prescription quality [44, 46], whereas other trials showed
improvement of (part of ) the indicators [38, 39, 49]. Tri-
als reporting the effect of medication review on scores
for appropriateness of prescribing and medication use
also found conflicting results. Although medication re-
view improved prescribing appropriateness as measured
with the Medication Appropriateness Index (MAI) and
the Assessment of Underutilization of Medication Index
(AOU) [49], no effect was found on a composite score
reflecting appropriate prescribing of benzodiazepines,
NSAIDs and thiazide diuretics [44]. Finally, the effect of
medication review on adverse effects was inconclusive,
as one trial demonstrated that medication review
decreases adverse effects [50] and a second trial did not
show a significant effect [47].
Economical outcomes
Figure 4 shows the effect of medication review on drug
costs. Based on the data of nine trials with overall low
risk of bias, including 2511 intervention patients, no
conclusion could be drawn about the effect of medica-
tion review on drug costs (Additional file 2: Table S20).
Trials using various other outcome measures for drug
and supply costs did generally not observe effect of
medication review on costs [37, 51, 52], except for one
study demonstrating that medication review might
decrease drug and supply costs due to discontinuation
[51]. Inconclusive results were also observed with re-
spect to total healthcare costs, as two studies found a
positive effect of medication review on total healthcare
costs [32, 53], one study found a temporary positive ef-
fect [38] and two studies did not find any effect [37, 43].
Besides this, Burns et al found no decrease or increase
of costs related to non-drug GP visits, in patient days,
outpatient visits, domiciliary visits and primary care
visits due to medication review [32].
Sensitivity analyses
The sensitivity analysis with a more stringent threshold
for risk of bias (≥8; 2/3 of the attainable 12) yielded
similar results except for the number of falls per patient,
which changed from effective to inconclusive, see
Additional file 3. Based on the sensitivity analysis ex-
cluding large trials with high risk of bias from the best
evidence synthesis, twice the conclusion changed from
effective to inconclusive (number of drug-related prob-
lems (DRPs) and number of drugs), twice from incon-
clusive to not effective (number of patients falling and
drug costs), once from not effective to inconclusive
(number of emergency admissions) and once from in-
conclusive to a decreased quality of life (EQ-5D VAS),
see Additional file 4.
Discussion
This is the first systematic review exploring the effect of
medication review as an isolated intervention without
co-interventions during a short term (≤3 months) inter-
vention period (as advocated in most medication review
guidelines [4–10] and operationalized in practice). Fur-
thermore this systematic review provides an overview of
all outcome measures and selection criteria without ex-
clusion criteria based on patient characteristics. In this
study, a beneficial effect of medication review was found
on most drug-related outcome measures. However, min-
imal effect was observed on clinical outcomes, no effect
was found on quality of life and evidence was inconclu-
sive concerning the effect on economical outcome mea-
sures. Only seventeen trials (55%) were designated low
risk of bias.
The findings of this systematic review are in line with
the findings of other systematic reviews assessing the
effect of medication review, although these systematic
reviews used other inclusion criteria. Previously pub-
lished systematic reviews often focused on specific pa-
tients (e.g. elderly or hospitalized patients etc.) and/or
included trials with multifaceted interventions and/or
limited the scope to specific outcome measures.
First of all, the lack of effect of medication review on
clinical outcomes (e.g. mortality, number of hospital
admissions) observed in this systematic review is in line
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with the findings of other systematic reviews [16–22],
although Patterson found conflicting results concerning
hospital admissions [14]. In other systematic reviews a
positive effect of medication review on some clinical
outcomes was suggested only when non RCTs [21],
unpublished data [18], co-interventions [15, 18] and/or
lengthier interventions (> 3 months) [21] were included.
Secondly, no effect of medication review on quality of life
was found by this systematic review, which is also con-
firmed by other systematic reviews [14, 16, 17, 21, 23].
Thirdly, the effect of medication review on drug-related
outcomes (e.g. a decrease in the number of drug-related
problems and the number of drugs) found in this
systematic review was confirmed by other systematic
reviews [17, 19], although Patterson found no consistent
intervention effect on medication-related problems
across studies [14]. In addition, in these systematic re-
views an effect of medication review on some other
drug-related outcome measures (e.g. adherence, adverse
drug events, medication appropriateness) was reported
[14–17, 19, 21, 23]. Finally, based on this systematic
review, no conclusion could be drawn about the effect of
medication review on economical outcome measures,
including drug costs. These results were confirmed by
the majority of other systematic reviews, since only one
out of six other systematic reviews [23] reported effect
of medication review on certain subdomains of econom-
ical outcome measures [15–17, 19, 21, 23].
Thus, when the effect of medication review is assessed
in terms of how it is operationalized in practice (with
medication review as isolated intervention) and even
when this effect is assessed irrespective of the patient
population and on all available outcome measures, the
impact found on clinical outcomes and quality of life is
minimal, the observed effect on drug-related outcomes
is limited and the evidence about the effect on econom-
ical outcome measures is inconclusive. This requires
further elaboration of the possible explanations of these
findings. Several aspects seem to contribute to these
findings, including the 1) selection of patients, the 2)
interventions (how medication reviews are being opera-
tionalized in practice) and the 3) outcome measures and
follow-up time used in trials assessing the effect of medi-
cation review. Besides these explanations it might also
be the case that the hypothesis that medication review
significantly improves clinical outcomes, economical
outcomes and quality of life should be rejected.
A possible explanation for the lack of evidence about
the effect of medication review is that the 1) selection of
patients does not fit the aim of the intervention. If the
aim of medication review is, for example, decreasing
mortality or preventing patients from being admitted to
the hospital, one should select a population with high
risk for any of these events. Inclusion criteria often
mentioned in medication review trials are age 65-plus
and a minimum number of drugs used. Although age
and polypharmacy are predominantly positively as-
sociated with the risk of having drug-related problems
[54–59], several other risk factors (e.g. co-morbidity,
renal impairment, high risk medication) contributing to
the occurrence of DRPs and/or hospital admissions are
found in literature [54, 60–69]. This suggests that a
more sensitive selection of patients for medication re-
view in order to reduce the risk of hospital admission
and or death may increase the chance of demonstrating
an effect of medication review on these outcomes.
Consequently, another aim of the intervention (e.g.
increasing adherence) will require a different selection of
patients (e.g. lack of therapeutic effect, adherence
scores). A second explanation for the lack of evidence
about the effect of medication review might be the
heterogeneity of 2) the interventions. No golden standard
exists for how medication review should be operational-
ized in practice. Several implicit as well as explicit medi-
cation review methods are used [70]. Furthermore,
different levels of medication review are applied in daily
practice [10]. This limits the ability to compare the
results of trials assessing the effect of medication review.
In addition, the multidisciplinary character of medication
reviews is possibly a complicating factor. Often problems
are difficult to solve 1) as many care-practitioners are
involved and 2) as it is not always clear which healthcare
practitioner should be addressed and/or 3) as the respon-
sible physician may not agree with implementation of a
recommendation made by another healthcare practitioner.
Once the aims of medication review are known, one or
more consistent (international) definitions and accom-
panying operationalizations of medication review should
be put into practice. Uniform medication reviews are
easier to compare in systematic reviews, this will contrib-
ute to the ability to demonstrate effect of these interven-
tions. Finally, the lack of evidence about the effect of
medication review might be explained by 3) the outcome
measures and follow-up time used in trials assessing the
effect of medication review. The outcome measures used
in published RCTs examining the effect of medication
review are often broad outcome measures, as for instance
hospital admissions and all-cause mortality, which are
affected by multiple (also not drug related) factors.
Although in RCTs these outcome measures may be the
ideal outcome measures, since these reflect the overall
benefit/risk ratio of drug treatment, no effect of medi-
cation review on these outcome measures is found,
possibly because the intervention medication review is
not powerful enough to have impact on hospitalizations
and mortality. Therefore (clinical) outcome measures
should be chosen which fit 1) the aim of the medication
review (improve safety and (cost-)effectiveness of a
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patient’s medication use) and 2) are more disease/medi-
cation specific (e.g. blood pressure, HbA1c) [12, 71].
However, these more disease/medication specific out-
come measures should not only reflect the negative
effects, but also the positive effects of drug treatment.
Although it is often seen in medication review trials,
only reporting drug-related outcome measures (e.g.
DRPs, number of drugs, adverse events) is suboptimal,
as these outcome measures only focus on the disadvan-
tages of drug treatment. Furthermore the outcome
measures used are often heterogeneous, as for each
outcome a different set of outcome measures is used
per trial. This limits the ability to draw robust conclu-
sions. Standardization of outcome measures and time
of follow-up should be applied in order to increase the
ability to compare the results of trials assessing the
effect of medication review. For instance, as one of the
aims of the intervention is to improve the quality of life
of patients, a standard set of quality of life scores (e.g.
EQ-5D and SF-36) should be defined and subsequently
used in future research to measure the effect of medica-
tion review on quality of life.
In the meantime, it is also conceivable that even when
medication review is operationalized and/or investigated
as described above, it is not effective on clinical outcomes,
economical outcomes and quality of life. A possible
explanation is that medication review is a cross-sectional
intervention at an arbitrary moment during patient’s drug
therapy. However, it might be assumed that at specific
moments of drug therapy (e.g. when drugs are started,
adapted or stopped) the risk for preventable drug-related
problems causing negative clinical outcomes is higher.
These specific high-risk moments seem to be the best
occasion to apply medication optimization in order to
prevent clinically relevant drug-related problems. It can
therefore be suggested to redesign the cross-sectional
medication review to longitudinal medication therapy
management, directly from the start of a drug, targeting at
specific risk moments [72]. Furthermore a more integral
approach of pharmaceutical care will give room for medi-
cation improvement strategies to shift from a system
repairing overdue maintenance to a more individualized
approach. Problems related to prescribing according to
general guidelines should be solved by means of population
based interventions like for instance clinical rules. Other in-
terventions should be developed to address issues related to
a patient’s use of medication in the context of his medical
condition. For instance individualized medication coaching
consults with non-adherent patients or patients experien-
cing drug-related problems or adverse events.
A couple of limitations are associated with this system-
atic review. In order to provide a broad overview on the
literature about the effect of medication review, no in-
clusion criteria were applied with regard to outcome
measures. Consequently, in the best evidence syntheses,
both trials using a specific outcome measure as primary
outcome measure and trials using the outcome measure
as secondary outcome measure were included. This
possibly leads to underpowered trials being part of the
best evidence synthesis (BES). However, large trials (with
more power) have more impact in the BES. Further-
more, in the best evidence synthesis, it is theoretically
possible that a large trial with a high risk of bias has
decisive impact on both the overall risk of bias of a set
studies and the conclusion about the effect of medica-
tion review on a specific outcome measure. However,
only in 1/22 best evidence syntheses would the conclu-
sion change to effect (EQ-5D VAS), when studies with a
high risk of bias with a number of intervention patients
greater than the median number of intervention patients
of the trials would be excluded from the best evidence
synthesis. Finally a limitation might be the fact that only
RCTs were included in this systematic review, although it
was a deliberate choice not to include observational stud-
ies, as a randomized controlled trial is the most appropri-
ate study design to demonstrate effect of an intervention.
Besides these limitations, some remarks can be made
with regard to the robustness of the conclusions. Firstly,
only 55% of the included studies were designated a low
risk of bias, which results in a smaller body of evidence.
In a sensitivity analysis, increasing the threshold for the
risk of bias assessment to an arbitrary 2/3 of the attain-
able maximum score, the percentage of trials with low
risk of bias decreased to 39%. For medication review
trials, however, on the one hand it is reasonable to relax
the threshold to some extent when it comes to blindness
of the patient, care provider and outcome assessor. On
the other hand this may lead to an overestimation of
positive findings of assessor dependent outcome mea-
sures, for instance when a non-blinded assessor has to
assess whether an outcome is drug-dependent or not.
Secondly, the variety of the included patients and settings
in this systematic review should be considered. Although
no exclusion criteria based on patient characteristics may
have resulted in more power, this also may have led to
false negative results in subgroups. In other systematic
reviews, however, often no effect was found in these
subgroups.
Conclusions
Although an isolated medication review during a short
term intervention period (how it is mostly operational-
ized in practice) has an effect on most drug-related
outcomes, medication review has minimal effect on clin-
ical outcomes, no effect on quality of life and no conclu-
sion could be drawn about the effect on economical
outcome measures. Therefore, it should be considered to
stop performing cross-sectional medication reviews as
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standard care. It may also be considered to shift the focus
of research from cross-sectional medication review to
other strategies to improve the safety and (cost-)effective-
ness of drug treatment. If, despite this, research on the
effect of cross sectional medication review is still contin-
ued, high quality studies including high-risk patients and
using relevant outcome measures should be conducted to
assess if/when medication reviews can contribute to better
medication use and subsequent better clinical outcomes.
However, more effort should be put in the development
and evaluation of other medication improvement strat-
egies, like more individualized and longitudinal medica-
tion therapy management, targeting at specific risk
moments of drug treatment and targeting at problems
that patients experience themselves.
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